MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy?

Paul Dent1, Adly Yacoub, Steven Grant

  • 1Department of Biochemistry, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298, USA. pdent@hsc.vcu.edu

Insights

Interleukin-24 (IL-24) shows promise as a cancer therapy, effectively halting tumor cell growth and causing cell death. Its ability to enhance radiation therapy further supports its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cytokine Research

Background:

  • The cytokine MDA-7/IL-24 expression increases during terminal differentiation.
  • IL-24 is expressed at low levels or absent in tumor cells compared to normal cells.

Purpose of the Study:

  • To review the impact of IL-24 on tumor cell biology.
  • To explore strategies for enhancing IL-24's anti-tumor toxicity.

Main Methods:

  • Literature review of studies on IL-24's anti-cancer effects.
  • Analysis of clinical trial data for Ad.mda-7 (INGN 241).

Main Results:

  • IL-24 expression in tumor cells induces growth arrest and cell death.
  • IL-24 acts as a radiosensitizer, partly via reactive oxygen species (ROS) and endoplasmic reticulum stress.
  • Phase I trials indicate Ad.mda-7 (INGN 241) is safe with tumoricidal effects.

Conclusions:

  • IL-24 demonstrates significant therapeutic potential in cancer treatment.
  • Further research into enhancing IL-24's efficacy is warranted.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...